close

Agreements

1 202 203 204 205 206 212
Number of results: 4240

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-06-09 Novagali Pharma (France) Ardeo Health (USA) OCuSOFT (USA) Nova23041

distribution

Ophtalmological diseases Distribution agreement
2011-06-09 Isconova (Sweden) Crucell (J&J subsidiary - the Netherlands USA) Isconova’s adjuvant Matrix M™ HIIV, malaria

licensing

Infectious diseases - Parasitic diseases Licensing agreement
2011-06-08 Asterand (UK) Capsant Neurotechnologies (UK) isletOrganDOT™ Diabetes Licensing Metabolic diseases
2011-06-08 Merck KGaA, Merck Serono (Germany) Affectis Pharmaceuticals (Germany) oral compounds targeting P2X7 receptors Neurological diseases

development

commercialisation

CNS diseases Development agreement
2011-06-07 Erytech Pharma (France) Teva Pharmaceuticals (Israel) Graspa® (asparaginase encapsulated into red blood cells)

registration
marketing
distribution
commercialisation

Cancer - Oncology Commercialisation agreement
2011-06-07 Oxford BioMedica (UK) ImaginAb (USA - CA) in vivo diagnostic imaging agent using an antibody targeting Oxford Biomedica’s proprietary 5T4 tumour antigen solid tumours

R&D

Cancer - Oncology R&D agreement
2011-06-07 Pharming Group (Netherlands) MegaPharm (Israel) Ruconest® (Rhucin® in non-European territories - conestat alfa) acute angioedema attacks in patients with Hereditary Angioedema (HAE)

commercialisation

Rare diseases Commercialisation agreement
2011-06-07 Antitope (UK) NasVax (Israel) monoclonal therapeutic antibodies for the treatment of inflammatory and autoimmune diseases

R&D

Inflammatory diseases - Autoimmune diseases R&D agreement
2011-06-06 Cellectis (France) VitamFero (France) living attenuated vaccines parasite infections

R&D

development

licensing

Infectious diseases Licensing agreement
2011-06-06 Cellectis (France) Vitamfero (France) meganuclease technology for the design and development of a new generation of living attenuated vaccines.

R&D
licensing

Veterinary medicine Licensing agreement
2011-06-02 Evotec (Germany) Active Biotech (Sweden) small molecule modulators of a priority biological target

R&D

Immune diseases - Cancer R&D agreement
2011-06-02 BMS (USA) Roche (Switzerland) Yervoy® (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib metastatic melanoma

R&D

Cancer - Oncology R&D agreement
2011-06-02 Roche (Switzerland) Clovis Oncology (USA) in vitro PCR (Polymerase Chain Reaction) based EGFR companion diagnostic test non small cell lung cancer

development

Cancer - Oncology Development agreement
2011-05-31 MediGene (Germany) The Johns Hopkins University (USA) vaccine candidates derived from the AAVLP program HPV-associated cancer

R&D

CancerOncology R&D agreement
2011-05-30 Sanofi (France) DNDI (Switzerland) new treatments for nine neglected tropical diseases This agreement covers nine neglected tropical diseases : kinetoplastid diseases(leishmaniases, Chagas disease, and human African trypanosomiasis), helminth infections(lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis), and dracunculiasis,fascioliasis, and schistosomiasis.

R&D

Infectious diseasesParasitic diseasesTropical diseases Collaboration agreement
2011-05-26 Bayer Schering Pharma (Germany) Epitomics (USA) monoclonal antibody technology

Services

Services contract
2011-05-25 Rhenovia Pharma (France) Portmann Instruments (Switzerland) biosimulation services drug optimization technologies

promotion
commercialisation

CNS diseases Commercialisation agreement
2011-05-25 Evotec (Germany) PsychoGenics (USA) drug discovery solutions

collaboration

CNS diseases Collaboration agreement
2011-05-25 Cancer Research UK (UK) Cancer Research Technology (UK) Centella Therapeutics (USA) CEN-209 solid tumors

development
manufacturing
production

Cancer - Oncology Development agreement
2011-05-24 AstraZeneca (UK) Daiichi Sankyo (Japan) denosumab bone disorders stemming from bone metastasis

Co-promotion

Cancer - Oncology Distribution agreement